Bicara Therapeutics Inc (BCAX)

01:38 AM

What analysts say about Bicara Therapeutics Inc. stock outlookHigh-margin investment plays - jammulinksnews.com

01:38 AM

Jul 24, 2025

Is Bicara Therapeutics Inc. stock a good hedge against inflationExtraordinary profit generation - jammulinksnews.com

Jul 24, 2025

Jul 24, 2025

Will Bicara Therapeutics Inc. stock benefit from interest rate changesDynamic investment growth - jammulinksnews.com

Jul 24, 2025

Jul 24, 2025

Is Bicara Therapeutics Inc. a good long term investmentConsistently exceptional gains - Autocar Professional

Jul 24, 2025

Jul 23, 2025

Bicara Therapeutics Inc. Stock Analysis and ForecastFree Investment Community - jammulinksnews.com

Jul 23, 2025

Jul 23, 2025

What drives Bicara Therapeutics Inc. stock priceHigh-velocity gains - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

What analysts say about Bicara Therapeutics Inc. stockHigh-profit trading signals - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

How Bicara Therapeutics Inc. stock performs during market volatilityVolume Spike Monitors - Newser

Jul 22, 2025

Jul 17, 2025

Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Price Target at $31.86 - Defense World

Jul 17, 2025

Jul 15, 2025

Why Bicara Therapeutics Inc. stock attracts strong analyst attentionFree Step-by-Step Investment Guide - Newser

Jul 15, 2025

Jul 15, 2025

What makes Bicara Therapeutics Inc. stock price move sharplyInvestor Friendly Risk Reward - Newser

Jul 15, 2025

Jul 08, 2025

Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III - Yahoo Finance

Jul 08, 2025

Jun 25, 2025

GAMMA Investing LLC Purchases 7,694 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Jun 25, 2025

Jun 12, 2025

Bicara Therapeutics Elects New Directors at Annual Meeting - TipRanks

Jun 12, 2025

Jun 12, 2025

Petri Dish: Scorpion spinout debuts with $177M, Bicara doubles footprint - The Business Journals

Jun 12, 2025

Jun 11, 2025

# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial - Investing.com

Jun 11, 2025

Jun 11, 2025

Relay Therapeutics Strengthens Board with Precision Medicine Expert as Phase 3 Cancer Trial Approaches - Stock Titan

Jun 11, 2025

Jun 11, 2025

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha

Jun 11, 2025

Jun 11, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Holdings Raised by Bank of America Corp DE - Defense World

Jun 11, 2025

Jun 11, 2025

Cantor Fitzgerald Estimates BCAX FY2026 Earnings - Defense World

Jun 11, 2025

Jun 10, 2025

Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update - MSN

Jun 10, 2025

Jun 10, 2025

Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria

Jun 10, 2025